Karyopharm - oncology

Quote




anonymous said:
our boss, little dickey really driving this thing right into ground. what a trainwreck....please step down, it's almost more necessary than Biden. When Rp looks worst than Biden, you know you gots big problems. wtf.....step down rookie
Click to expand...
well said. RP has been a complete and utter failure. How is it the siendo 2 is not enrolled yet on such great data. This failure falls squarely on his shoulders. This will also lead to not meeting runaway which is another failure. Where the hell is the BOD on these failures. Please step down for the good of us employees and patients.
 








I don’t know why any of this should come as a surprise. He has zero record of accomplishment. The only thing he’s been good at is figuring out how to fall up into his next position (usually just about the time the place he’s at is getting ready to push him out the door). Educational credentials are mediocre. We probably shouldn’t even talk about the misfits he’s hired and surrounded himself with.
 




















anonymous said:
Down over 90% since h1 2021. Little Dicky!
Click to expand...
the plane crashed on the runway....how is that even possible......he first crashed with lack of rev growth and cancelled or failed or pushed out trials.......now he has failed to get enough fuel to get us down runway. Is this "Captain" even monitoring his gauges ?? Does he even know how to read them or pilot accordingly ?? Never seen a "Captain" asleep at the helm like RP, our diligent boss.
 




anonymous said:
the plane crashed on the runway....how is that even possible......he first crashed with lack of rev growth and cancelled or failed or pushed out trials.......now he has failed to get enough fuel to get us down runway. Is this "Captain" even monitoring his gauges ?? Does he even know how to read them or pilot accordingly ?? Never seen a "Captain" asleep at the helm like RP, our diligent boss.
Click to expand...
Totally agree and what’s sad is upon pushing out MK the BOD placed an unproven first time CEO to get us through this…it’s was an odd choice. Even a savvy, tenured CEO would have had their challenges with KPTI, but throwing a first timer with an unimpressive pedigree both professionally and academically at it was a recipe for disaster.
 




padnarsertib received FDA orphan status for Ewing Sarcoma, yet investor relations says nothing about it. The last headline on Yahoo Finance is 8 days ago about inducement grants for new hires. Who is supposed to announce this and when?
 




anonymous said:
padnarsertib received FDA orphan status for Ewing Sarcoma, yet investor relations says nothing about it. The last headline on Yahoo Finance is 8 days ago about inducement grants for new hires. Who is supposed to announce this and when?
Click to expand...
Too busy drafting the SEC form 25 and getting a contract in place with Goulston & Storrs
 




anonymous said:
padnarsertib received FDA orphan status for Ewing Sarcoma, yet investor relations says nothing about it. The last headline on Yahoo Finance is 8 days ago about inducement grants for new hires. Who is supposed to announce this and when?
Click to expand...
what's the difference, this crew couldn't deliver a pizza pie let alone and new indication
 




anonymous said:
what's the difference, this crew couldn't deliver a pizza pie let alone and new indication
Click to expand...
I do not believe that getting an orphan status designation is worthy of a press release, especially in this instance. You see very few press releases by companies for the designation...when the drug receives its approval under the Orphan Drug Act that is when it becomes newsworthy as the company will benefit from additional funding, tax breaks, and exclusivity. While they will get some funding help through the ODA for clinical trials and development, only about 20%-30% ever get approved so it is still a hefty spend for a low chance of FDA approval. That is my guess as to why a press release has not happened as investors may get spooked to see a company like KPTI, with limited funds and a financial cliff looming ahead, spending any additional resources on assets with low market potential and low a likelihood of approval, even with government funding assistance. Companies in KPTI's situation tend to bury these events unless required by law to disclose. Additionally, KPTI may very well sell off this asset to a Big Pharma to get some guarantee of revenue off to it.
 




















Here’s a list of what’s happened since he took over in 2021. It kind of makes you wonder what - if anything - the board would consider worthy of termination.

Share price down over 90%
Sales moribund/declining
Quarterly consensus estimates for sales or profit missed about half the time
Company removed from Russell 3000
Key development timeless missed
Pending nasdaq delisting because stock trades below $1
 








Top Bottom
Back
Quote